Lv2
150 积分 2022-04-02 加入
1393P Phase I/II clinical trial of combination of anti-PD-1 mAb, nivolumab with radiotherapy for unresectable and recurrent gastric cancer who failed to standard chemotherapy
1天前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
1天前
已完结
The additional radiotherapy to adjuvant chemotherapy improves the prognosis of stage III-N2 with highest mediastinal lymph node metastasis in non-small cell lung cancer
1天前
已完结
Concurrent Involved-field Radiotherapy and XELOX Versus XELOX Chemotherapy Alone in Gastric Cancer Patients With Postoperative Locoregional Recurrence
17天前
已完结
LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
1个月前
已关闭
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
1个月前
已完结
FRUTIGA: Oral VEGFR Inhibitor Fruquintinib Prolongs PFS When Added to Second-Line Paclitaxel in G/GEJ Adenocarcinoma
1个月前
已关闭
PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC)
1个月前
已完结
Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study
1个月前
已完结
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
1个月前
已完结
皖公网安备34019202002308
